# Trem1 regulates neutrophil metabolism and recruitment in lung ischemia-reperfusion injury

**Authors:** Fengjing Yang, Song Tong, Junhao Wan, Yixing Li, Jiani Gao, Yan Sun, Xiangfu Sun, Huikang Fu, Wenzhuo Luo, Jiayang Xu, Ting Zhou, Sowe Babou, Junqi Wu, Guangjian Zhang, Chang Chen, Sihua Wang

PMC · DOI: 10.1016/j.redox.2026.104026 · 2026-01-14

## TL;DR

This study shows that Trem1 influences neutrophil metabolism and recruitment in lung injury after transplantation, suggesting it could be a target for improving transplant outcomes.

## Contribution

The study identifies Trem1 as a novel regulator of neutrophil metabolism and recruitment in lung ischemia-reperfusion injury.

## Key findings

- Trem1 deficiency reduces neutrophil recruitment, NET formation, and tissue damage in lung IRI.
- Trem1 deletion shifts neutrophil metabolism from oxidative phosphorylation to glycolysis.
- TREM1+ neutrophil abundance correlates with primary graft dysfunction severity in clinical samples.

## Abstract

Primary graft dysfunction (PGD) caused by ischemia-reperfusion injury (IRI) is a major complication after lung transplantation, yet its underlying mechanisms remain unclear. Triggering receptor expressed on myeloid cells 1 (Trem1) is an important mediator of inflammation, but its role in neutrophil function and metabolic reprogramming during lung IRI is not well understood. In this study, we used a murine orthotopic lung transplantation model with cold ischemia and reperfusion, and Trem1 knockout (Trem1−/−) and myeloid-specific Trem1 conditional knockout mice (LysmCreTrem1fl) to explore the role of Trem1 in neutrophil recruitment, neutrophil extracellular trap (NET) formation, and metabolism. Our results show that Trem1 expression increases in both mouse and human lungs after reperfusion and correlates with neutrophil infiltration and lung injury. Trem1 deficiency significantly reduced neutrophil and macrophage recruitment, NET formation, and tissue damage. Multi-omics analysis revealed that Trem1 deletion suppressed oxidative phosphorylation (OXPHOS) and induced a metabolic shift in neutrophils toward glycolysis. In clinical samples, the abundance of TREM1+ neutrophils was correlated with PGD severity and OXPHOS activity. These findings identify Trem1 as a key regulator of neutrophil metabolism and recruitment in lung IRI, and suggest that targeting Trem1 may provide a novel therapeutic strategy to mitigate PGD and improve lung transplant outcomes.

Image 1

## Linked entities

- **Genes:** TREM1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 54210]
- **Diseases:** ischemia-reperfusion injury (MONDO:0005203)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Trem1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 58217], Hk1 (hexokinase 1) [NCBI Gene 15275] {aka Hk-1, Hk1-s, dea, mHk1-s}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, Atf3 (activating transcription factor 3) [NCBI Gene 11910] {aka LRG-21}, Gdnf (glial cell line derived neurotrophic factor) [NCBI Gene 14573] {aka ATF}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Idh2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial) [NCBI Gene 269951] {aka E430004F23, IDPm, Idh-2}, Fcgr2b (Fc receptor, IgG, low affinity IIb) [NCBI Gene 14130] {aka CD32, F630109E10Rik, Fc[g]RII, FcgRII, Fcgr2, Fcgr2a}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Marcksl1 (MARCKS-like 1) [NCBI Gene 17357] {aka D4Bc1, F52, MacMARCKS, Macs2, Macs3, Mlp}, Fcgr3 (Fc receptor, IgG, low affinity III) [NCBI Gene 14131] {aka CD16}, TREM1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 54210] {aka CD354, TREM-1}, Ccl3 (C-C motif chemokine ligand 3) [NCBI Gene 20302] {aka G0S19-1, LD78alpha, MIP-1alpha, MIP1-(a), MIP1-alpha, Mip1a}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Pkm (pyruvate kinase, muscle) [NCBI Gene 18746] {aka Pk-2, Pk-3, Pk3, Pkm2}, Atf1 (activating transcription factor 1) [NCBI Gene 11908], ATF3 (activating transcription factor 3) [NCBI Gene 467], Junb (jun B proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16477], Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Atf7 (activating transcription factor 7) [NCBI Gene 223922] {aka 1110012F10Rik, 9430065F09Rik, C130020M04Rik}, H3c7 (H3 clustered histone 7) [NCBI Gene 260423] {aka H3.2-221, H3c13, H3c14, H3c15, H3c2, H3c3}, Creb1 (cAMP responsive element binding protein 1) [NCBI Gene 12912] {aka 2310001E10Rik, 3526402H21Rik, Creb, Creb-1}, Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 14281] {aka D12Rfj1, c-fos, cFos}, Atp5mc1 (ATP synthase membrane subunit c locus 1) [NCBI Gene 11951] {aka Atp5g1}, MPO (myeloperoxidase) [NCBI Gene 4353], Atf2 (activating transcription factor 2) [NCBI Gene 11909] {aka Atf-2, CRE-BP, Creb2, D130078H02Rik, Tg(Gzma-Klra1)7Wum, mXBP}
- **Diseases:** dysfunction (MESH:D006331), end-stage lung diseases (MESH:D058625), acute graft injury (MESH:D001930), NET (MESH:C536657), hemorrhage (MESH:D006470), injury (MESH:D014947), obliterative bronchiolitis (MESH:D001988), PGD (MESH:D055031), Ischemia (MESH:D007511), lung (MESH:D008171), IRI (MESH:D015427), lung injury (MESH:D055370), tissue injury (MESH:D017695), sepsis (MESH:D018805), acute lung injury (MESH:D055371), obliterative (MESH:C538011), ischemic (MESH:D002545), organ injury (MESH:D009102), inflammation (MESH:D007249), edema (MESH:D004487), neutrophil (MESH:C564275)
- **Chemicals:** fructose-6-phosphate (MESH:C027618), Oxygen (MESH:D010100), ethanol (MESH:D000431), Alexa Fluor (-), PVDF (MESH:C024865), oligomycin (MESH:D009840), rotenone (MESH:D012402), uranyl acetate (MESH:C005460), fumarate (MESH:D005650), TRIzol (MESH:C411644), Perfadex (MESH:C070005), TCA (MESH:D014238), sedoheptulose-7-phosphate (MESH:C020495), paraformaldehyde (MESH:C003043), SDS (MESH:D012967), eosin (MESH:D004801), H&amp;E (MESH:D006371), inosine (MESH:D007288), FCCP (MESH:D002259), paraffin (MESH:D010232), epoxy (MESH:D004853), alpha-ketoglutarate (MESH:D007656), formalin (MESH:D005557), 3,3',5,5'-tetramethylbenzidine (MESH:C021758), fructose-1,6-bisphosphate (MESH:C029063), glucose (MESH:D005947), antimycin A (MESH:D000968), osmium tetroxide (MESH:D009993), water (MESH:D014867), Hematoxylin (MESH:D006416), ATP (MESH:D000255), glucose-6-phosphate (MESH:D019298), glutaraldehyde (MESH:D005976)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13019080/full.md

---
Source: https://tomesphere.com/paper/PMC13019080